Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997026887 - USE OF GALANTHAMINE IN THE PREPARATION OF NOVEL DRUGS

Publication Number WO/1997/026887
Publication Date 31.07.1997
International Application No. PCT/AT1997/000011
International Filing Date 27.01.1997
Chapter 2 Demand Filed 26.08.1997
IPC
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
CPC
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
Y02A 50/30
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection, e.g. against extreme weather
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applicants
  • SANOCHEMIA LTD. [MT]/[MT] (AllExceptUS)
  • MUCKE, Martin, Alois, Hermann [AT]/[AT] (UsOnly)
  • FRANTSITS, Werner [AT]/[AT] (UsOnly)
Inventors
  • MUCKE, Martin, Alois, Hermann
  • FRANTSITS, Werner
Agents
  • BEER, Otto
Priority Data
A 149/9626.01.1996AT
Publication Language German (DE)
Filing Language German (DE)
Designated States
Title
(DE) VERWENDUNG VON GALANTHAMIN ZUM HERSTELLEN VON NEUEN ARZNEIMITTELN
(EN) USE OF GALANTHAMINE IN THE PREPARATION OF NOVEL DRUGS
(FR) UTILISATION DE GALANTHAMINE POUR PREPARER DE NOUVEAUX MEDICAMENTS
Abstract
(DE)
Verwendung von Galanthamin oder eines Säureadditionssalzes desselben zum Herstellen eines Arzneimittels zur Behandlung von Trisomie 21 und verwandten Syndromen, zur Behandlung des Glaukoms, für die Behandlung der Myasthenia gravis sowie mit dieser verwandter neuromuskulärer Autoimmunkrankheiten und/oder für die Behandlung des Nervenkompressionstraumas.
(EN)
Described is the use of galanthamine or one of its acid addition salts in the preparation of a drug for the treatment of trisomia 21 and related syndromes, glaucoma, myasthenia gravis and neuromuscular auto-immune illnesses and/or nerve-compression trauma.
(FR)
L'invention concerne l'utilisation de galanthamine ou d'un de ses sels d'addition d'acide pour préparer un médicament s'utilisant dans le traitement de la trisomie 21 et des syndromes apparentés, pour traiter le glaucome, la myasthénie grave, ainsi que les maladies neuromusculaires auto-immunes apparentées et/ou le traumatisme de compression nerveuse.
Also published as
Latest bibliographic data on file with the International Bureau